How Much Does a Patient Support Program Cost in Egypt? A Budget Framework for Pharma Brand Teams
Quick answer
"It depends" is not a useful answer to someone building a launch business case. Here is the structure behind PSP pricing in Egypt, what is bundled, what is billed separately, and the five questions to answer before requesting a quote.
Every brand manager who has ever scoped a patient support program in Egypt has hit the same wall: they ask a provider what it costs, and the answer is "it depends." That answer is technically true and practically useless. Finance does not accept "it depends" in a launch business case, and a brand team that cannot put a defensible number against a PSP line usually ends up either under-budgeting a program into failure or dropping it from the plan altogether.
This guide does not quote a price, because any provider quoting a headline per-patient figure before seeing your enrollment forecast is guessing. What it does instead is more useful: it explains exactly which variables move PSP pricing in Egypt, in order of impact, so you can build a credible internal estimate and walk into a vendor conversation already knowing what you are buying.
The cost drivers, in order of impact
PSP pricing is not arbitrary. It is a function of how many patients you expect, how far apart they are, how much clinical time each one needs, how long the program runs, and how much reporting the sponsor requires. Those five variables explain the overwhelming majority of the difference between one program's cost and another's.
| Cost driver | What it changes | Budget impact |
|---|---|---|
| Forecast enrollment volume | Fixed program overhead spreads across more or fewer patients | Highest — the single biggest lever on per-patient cost |
| Geographic spread | Cairo/Alexandria only vs. nationwide governorate coverage, with the travel time and nurse network that implies | High — nationwide coverage carries a structurally different cost base |
| Service intensity | Phone follow-up only vs. home injection or infusion visits with monitoring windows | High — clinical visit time is the largest variable cost in any program |
| Program duration | A 6-month pilot vs. a 3-year chronic therapy program | Medium — longer terms amortize setup and usually improve unit economics |
| Reporting and KPI complexity | A monthly KPI pack vs. bespoke dashboards, global HQ formats, and safety-aligned reporting workflows | Medium — mostly a setup and analyst-time cost, not a per-patient one |
Two of these deserve a closer look because they are the ones brand teams most often underestimate. Geographic spread is not a linear multiplier: extending a program from Greater Cairo to full governorate coverage does not simply add patients, it requires a nurse network, credentialing, and scheduling capacity in places where none of that exists yet. And service intensity is where oral therapy programs and injectable programs stop being comparable — a program built around monthly home injections carries a cost structure that has almost nothing in common with one built around refill reminder calls.
Per-patient vs. flat monthly pricing — which fits which program
Providers in this market typically propose one of two commercial models, and the right one depends less on your negotiating preference than on how confident you are in your enrollment forecast.
| Model | How it works | Fits best when | Main risk to the sponsor |
|---|---|---|---|
| Per-patient (per enrolled patient, per period) | You pay for patients actually enrolled and served | Enrollment is uncertain, the therapy is new, or you are piloting before a national rollout | Costs scale faster than expected if the program over-performs on enrollment |
| Flat monthly program fee | You pay a fixed fee for a defined service scope and capacity band | Enrollment is predictable, or coverage capacity must exist regardless of volume | Paying for capacity you do not use if enrollment lands below forecast |
| Hybrid (base fee + per-visit component) | A fixed operational base covers coordination and reporting; clinical visits bill separately | Programs where visit frequency varies widely between patients | Requires disciplined visit tracking and a clear definition of a billable visit |
The practical advice here is simple and it is the single most valuable sentence in this guide: ask your provider to model both against your forecast enrollment, at your forecast, at half of it, and at double it. A provider who can produce that three-scenario model quickly understands their own cost base. A provider who cannot is either inexperienced or hoping you will not notice where the break-even sits.
Share your expected enrollment, therapy area, and geographic scope, and our clinical and operations team will model both commercial structures against your numbers.
Request a cost modelWhat is usually bundled vs. billed separately
Most disputes between pharma sponsors and PSP vendors in this market are not about the headline rate. They are about scope: what the base fee was assumed to include. Clarifying this before signature is worth more than negotiating a few percent off the number.
| Component | Usually included in the base program fee | Commonly billed separately |
|---|---|---|
| Patient enrollment and onboarding | Yes — referral intake, welcome contact, consent handling | High-volume enrollment campaigns or physician-facing activation |
| Contact-center follow-up | Yes — scheduled adherence and refill follow-up calls | Extended hours, additional languages, or out-of-scope call volume |
| Home nursing visits | Sometimes, in a defined visit allowance per patient | Additional visits, infusion-grade visits, and long-distance travel |
| Adherence and KPI reporting | Yes — a standard monthly KPI pack | Bespoke dashboards, HQ-specific formats, ad hoc analyses |
| Safety / PV-aligned reporting workflow | Yes — capture and escalation per the agreed pathway | Bespoke system integration with the sponsor's own safety database |
| Patient education materials | Standard bilingual materials | Brand-specific creative, printing at scale, custom translation |
The hidden cost of running a PSP in-house
Our companion guide on building versus outsourcing a PSP covers the strategic side of that decision. The financial lens is narrower and harder to argue with: an in-house program's line-item cost is almost never the true cost, because most of what makes a PSP work never appears on the budget sheet.
- Recruitment and clinical hiring: sourcing, vetting, and credentialing nurses in multiple governorates is a recurring cost, not a one-off, because clinical staff turnover in field roles is real and each replacement resets the training clock.
- Training and quality assurance: injection technique, cold-chain handling, adverse-event recognition, and documentation standards all need to be trained, refreshed, and audited — a fixed annual cost the sponsor absorbs entirely.
- Geographic coverage gaps: an in-house team covers the cities it was staffed for. Every patient outside that footprint is either a cost exception or an unserved enrollment, and the latter quietly undermines the enrollment forecast the whole business case rested on.
- Idle capacity between peaks: a program with seasonal or launch-phase enrollment swings pays for the same team in slow months as in peak months, where an outsourced model flexes.
- Brand-team opportunity cost: the most expensive hidden line is the medical affairs and brand manager time spent on rostering, escalations, and vendor logistics instead of on the market access and physician engagement work only they can do.
None of this means in-house is always wrong. For a very high-volume, single-city, long-duration program, the economics can work. But the comparison is only honest when all five of these lines are in the model.
A five-question worksheet before you request a quote
Answer these five before any vendor conversation. With them, you will receive comparable proposals. Without them, you will receive five proposals that cannot be placed side by side.
- Forecast enrollment: how many patients do you expect to enroll in months 1–6, and in a steady-state year? State the assumption behind the number, not just the number.
- Geographic scope: Greater Cairo and Alexandria only, a named list of governorates, or nationwide? Coverage ambition is the second-biggest cost driver and the most commonly left vague.
- Therapy complexity: oral, self-injected, nurse-administered injection, or infusion? This determines whether you are buying coordination or clinical delivery.
- Reporting requirements: what does your global HQ need to see, in what format, and how often? Bespoke reporting is cheap to specify up front and expensive to retrofit.
- Contract length: pilot, one year, or multi-year? Duration is a legitimate lever on pricing and should be raised by you before it is offered to you.
Our patient support programs cover enrollment, home nursing, adherence follow-up, and monthly KPI reporting for pharma partners across Egypt.
Explore patient support programsFrequently asked questions
Is PSP pricing different for biologics and injectables compared with oral therapies?
Yes, substantially. An oral therapy program is built around coordination — enrollment, education, adherence follow-up, and reporting — which is largely a contact-centre and analyst cost. An injectable or infusion program adds qualified clinical time in the patient's home for every administration, plus cold-chain handling, technique verification, and a post-administration monitoring window. That clinical visit time is the largest single variable cost in any PSP, which is why the two program types should never be benchmarked against each other on a per-patient basis.
Can we run a pilot at smaller scale before committing to a national rollout?
Yes, and for a newly launched therapy it is usually the right sequence. A pilot in one or two governorates lets you validate the referral pathway, the real enrollment rate against forecast, and the visit frequency patients actually need — all of which make the national model far more accurate. The trade-off is unit economics: a pilot carries the same setup and reporting overhead across fewer patients, so expect a higher per-patient cost than steady state, and treat that premium as the price of a validated forecast.
What happens to cost if actual enrollment comes in below forecast?
It depends entirely on the commercial model you signed. Under a per-patient structure, cost falls with enrollment and the risk sits mostly with the provider. Under a flat monthly fee, you are paying for reserved capacity whether it is used or not. This is exactly why we recommend modelling both structures at your forecast, at half of it, and at double it before signature — the question is not which model is cheaper, but which one you can live with if the forecast is wrong in either direction.
